Atomera Incorporated (ATOM) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Atomera Inc (ATOM) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Atomera is a tiny semiconductor materials IP company that is trying to turn its transistor-film technology into licensing revenue—but right now it still looks much more like a commercialization story than a proven business. > **📍 Basic Profile** > > Market Cap **$0.33 billion** · Semiconductors · NASDAQ NMS - GLOBAL MARKET · Price **$8.60** > **⚡ 3 Things You Should Know** > > 1. 💰 Not a cash machine yet: The company’s margins are deeply negative and PE is unavailable because it is still losing money, which basically means investors are paying for future licensing potential, not current earnings. > > 2. 📈 The stock is trading like a breakthrough story: Shares jumped nearly 39% in a day and are sitting at the 52-week high after the Synopsys collaboration news, so sentiment is hot—but that also means expectations may have moved ahead of fundamentals. > > 3. ⚠️ Financially safe for now, operationally unproven: Atomera has very low leverage and a strong current ratio, so bankruptcy risk does not look immediate, but revenue is tiny and shrinking over the 3-year period, which tells you adoption is still the make-or-break issue. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -23395.38%, far below industry norms | > | Growth Rate | Slow🐢 | 3-year revenue growth -44.49% | > | Financial Health | Healthy💚 | Debt-to-equity 0.02, current ratio 9.80 | > | Valuation | Expensive | PE unavailable; PS 5123.35x implies extreme future expectations | ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Atomera develops semiconductor materials technology and licenses it to chipmakers and ecosystem partners, aiming to make money through royalties, technology agreements, and related engineering collaborations. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Technology licensing / collaboration revenue | [Data unavailable] | ↓ | Revenue base appears very small and inconsistent | | Semiconductor IP / materials development partnerships | [Data unavailable] | ↑ | Recent GaN and Synopsys-related activity suggests pipeline building, but monetization is still early | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | -298.46% | Below Average | Costs are far above revenue, which usually happens when revenue is too small to absorb R&D and operating structure | | Net Margin | -23395.38% | Below Average | In other words, this is still a pre-scale business, not a mature semiconductor company | | ROE | -98.43% | Average | Losses are heavily eroding returns on shareholder capital | --- #### 📈 How's the Growth? **Growth Assessment:** Slowing | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What’s interesting is that the growth story here is more about future deal flow than current financial output. The 3-year revenue trend is sharply negative, so this is not healthy scaled growth yet. If growth does show up, it will likely come from commercialization milestones, new license deals, or royalty ramps—not from a broad existing revenue engine. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a startup with a well-funded balance sheet and very little debt, but not yet enough real income to support itself comfortably from operations. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0.02% | <60% safe | ✅Safe | | Current Ratio | 9.80 | >1.5 healthy | ✅Safe | | Cash Flow | [Data unavailable] | >0 | ⚠️Volatile | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $1.89 - 52-Week High: $9.59 - Current: $8.60, Very close to high | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(87% position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PS 5123.35x | Industry avg [Data unavailable] | Likely far above peers | **What the Current Valuation is Betting On:** > Basically, the market is betting Atomera’s technology will actually land in commercially meaningful semiconductor production flows. At this price, investors are not paying for what the company earns today—they’re paying for the possibility that partnerships like Synopsys help validate the tech and unlock future licensing revenue. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-23 | Expanded collaboration with Synopsys for GaN device modeling | Positive — this strengthens technical credibility and may help Atomera get closer to real design wins | | 2026-04-24 | Stock surged after Synopsys collaboration announcement | Neutral to Positive — good for momentum, but the move also raises near-term speculation risk | | 2026-04-21 | Announced upcoming Q1 2026 financial results and webinar | Neutral — next earnings update matters because investors need proof that technical partnerships are translating into revenue | ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | -298.46% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -23395.38% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -98.43% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↓ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | -$0.14 | -$0.10 | +30.0% Beat 😀 | | 2025-09-30 | -$0.13 | -$0.13 | +2.0% Beat 😀 | | 2025-06-30 | -$0.14 | -$0.12 | +16.0% Beat 😀 | | 2025-03-31 | -$0.13 | -$0.14 | -5.6% Miss 😟 | **Earnings Trend Interpretation:** The good news is Atomera has beaten estimates in 3 of the last 4 quarters. The catch is that these are still losses, so the message is more “burning cash a bit slower than feared” than “business model proven.” --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 6 firms | 85.7% | | Hold | 1 firm | 14.3% | | Sell | 0 firms | 0.0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net buying **not clearly determinable from provided data** in past 3 months > Worth noting: the insider records shown are mostly transaction code “A,” which often indicates award or grant rather than open-market buying. So it would be a mistake to read this as a strong insider conviction signal without more detail. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Commercialization Risk:** Atomera may have promising semiconductor materials technology, but if customers do not move from collaboration to volume adoption, it could lead to continued tiny revenue and recurring losses. 2. **Valuation Risk:** With no earnings and an extreme price-to-sales multiple, the stock is highly sensitive to disappointment → If revenue traction slips, the share price could correct sharply. 3. **Volatility Risk:** Beta above 2 and a near-39% one-day jump show this name can move violently → If sentiment cools or small-cap tech appetite weakens, it could lead to outsized downside swings. ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Atomera is a speculative semiconductor materials licensing company whose value depends on whether its technology becomes commercially adopted by larger industry players. > > **Key strength:** Its balance sheet looks clean, and the Synopsys collaboration gives it a meaningful credibility boost in advanced semiconductor applications like GaN. > > **Key risk:** The business still has extremely weak current fundamentals, so the stock is being priced mainly on hope, validation, and future deal conversion. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis